EUVIMEDEUVIMED entdecken
Crossref

Identification of effective CCR2 inhibitors for cancer therapy using humanized mice

Shigeaki Sugiyama, Kanae Yumimoto, Shun Fujinuma, Keiichi I Nakayama

The Journal of Biochemistry · 2024

DOI: 10.1093/jb/mvad086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Biochemistry, 2024. Verfasst von Shigeaki Sugiyama und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka 812…. Hauptthemen laut MEDLINE: Receptors, CCR2, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: FOREST Program of the Japan Science and Technology Agency, KAKENHI grants from the Japan Society for the Promotion of Science (JSPS), Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from Japan Agen….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

C-C chemokine receptor type 2 (CCR2) is the receptor for C-C motif chemokine 2 (CCL2) and is associated with various inflammatory diseases and cancer metastasis. Although many inhibitors for CCR2 have been developed, it remains unresolved which inhibitors are the most effective in the clinical setting. In the present study, we compared 10 existing human CCR2 antagonists in a calcium influx assay using human monocytic leukemia cells. Among them, MK0812 was found to be the most potent inhibitor of human CCR2. Furthermore, we generated a human CCR2B knock-in mouse model to test the efficacy of MK0812 against a lung metastasis model of breast cancer. Oral administration of MK0812 to humanized mice did indeed reduce the number of monocytic myeloid-derived suppressor cells and the rate of lung metastasis. These results suggest that MK0812 is the most promising candidate among the commercially available CCR2 inhibitors. We propose that combining these two screening methods may provide an excellent experimental method for identifying effective drugs that inhibit human CCR2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CCR2Lung NeoplasmsHumansAnimalsMiceChemokine CCL2MonocytesDisease Models, Animal

Stichwörter der Autor:innen

C-C chemokine receptor type 2 (CCR2)cancer metastasisknock-in miceknockout micemonocytic myeloid-derived suppressor cells (M-MDSCs)

Substanzen

Receptors, CCR2Chemokine CCL2CCR2 protein, human

Autor:innen und Institutionen

  • Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka 812-8582, Japan.
  • Anticancer Strategies Laboratory, TMDU Advanced Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.

Förderung

  • FOREST Program of the Japan Science and Technology Agency
  • KAKENHI grants from the Japan Society for the Promotion of Science (JSPS)
  • Research Support Project for Life Science and Drug Discovery (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)) from Japan Agen…

Zitieren

APA

Sugiyama, S., Yumimoto, K., Fujinuma, S., & Nakayama, K. I. (2024). Identification of effective CCR2 inhibitors for cancer therapy using humanized mice. The Journal of Biochemistry. https://doi.org/10.1093/jb/mvad086

Vancouver

Sugiyama S, Yumimoto K, Fujinuma S, Nakayama KI. Identification of effective CCR2 inhibitors for cancer therapy using humanized mice. The Journal of Biochemistry. 2024. doi:10.1093/jb/mvad086

BibTeX
@article{Sugiyama2024,
  author = {Sugiyama, Shigeaki and Yumimoto, Kanae and Fujinuma, Shun and Nakayama, Keiichi I},
  title = {Identification of effective CCR2 inhibitors for cancer therapy using humanized mice},
  journal = {The Journal of Biochemistry},
  year = {2024},
  doi = {10.1093/jb/mvad086}
}
Kostenlos starten →